Company Profile

Industry Sector: Personalized Medicine/Clinical Laboratory Diagnostics

Company Overview: PGXL Laboratories is a pioneer and industry leader in providing pharmacogenomic testing and diagnostic information to both researchers and healthcare providers. For five years the company has been among the nation’s leading providers of pharmacogenetic testing services, and has now developed technology that will enable the mass application of pharmacogenetic knowledge to personalized medicine.

Target Markets: Personalized Medicine targeting areas in:
- Cardiovascular (anticoagulation)
- Oncology
- Pain Management
- Behavioral Health (psychiatry)

Key Value Drivers

Technology: Interconnected pharmacogenetic testing services and software enabling the fast and accurate interpretation and application of pharmacogenetic test results for optimum patient management. Unique product is PerMIT, a web-based program that simplifies the development of dosing strategies for certain widely used medications, creating a faster, better and cheaper path to the wide adoption of personalized medicine.

Competitive Advantage: PerMIT is the essential bridge that has been lacking between pharmacogenomic research and the real-world implementation of personalized medicine. It is a proprietary software application, the only available decision-support tool that provides actionable and intelligent use of pharmacogenomic information for healthcare practitioners. The application generates real-time drug selection and dosing strategies based on most-current clinical research, eliminating or greatly reducing the trial-and-error approach traditionally used to establish stable dosing. It is particularly applicable to drugs commonly used in anticoagulation, oncology and psychiatry.

Plan & Strategy: Seeking a strategic partner or partners to commercialize PerMIT and related services.

Management

Leadership:
Dr. Roland Valdes Jr. (Chairman and President),
Dr. Mark W. Linder (Sr. Vice President, Operations)
Mr. Brad Esarey (Vice President, Sales and Marketing)
Dr. Kristen Reynolds (Vice President, Clinical Laboratory Services)
Ms. Laura DeSalvo (Financial Officer)

Board of Directors:
Dr. Roland Valdes Jr. (Chairman)
Dr. Mark W. Linder (Chief Science Officer)
Mr. Robert Proulx (VP Sales and Marketing, Nanogen)

Product Pipeline

www.permitwarfarin.com